Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.07% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTCrinetics Pharmaceuticals, Inc.'s latest supported as-filed period reports revenue of $25.1M, 2336.3% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.07% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -375.00% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 2336.28% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 13.89% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 99.39% · CORE
Level · gp.fundamentals.operating_margin
Raw value -527.35% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue changed across a low base; Operating margin moved 1199564 bp higher; Operating income decreased 2.6%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue changed across a low base; Operating margin moved 1199564 bp higher; Operating income decreased 2.6%.
3 evidence-backed componentsOperating margin changed +1199564 basis points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
CRNX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-059910SEC ↗4Sep 1, 2026Period Sep 1, 20260001628280-26-059907SEC ↗4Sep 1, 2026Period Sep 1, 20260001628280-26-059905SEC ↗4Sep 1, 2026Period Sep 1, 20260001628280-26-059904SEC ↗4Sep 1, 2026Period Sep 1, 20260001628280-26-059902SEC ↗4Sep 1, 2026Period Sep 1, 20260001628280-26-059901SEC ↗4Sep 1, 2026Period Sep 1, 20260001628280-26-059900SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 1, 2026Filed Sep 1, 2026 | Kalofonos IsabelChief Commercial Officer | Disposition To IssuerDirect | 1,669 | $85 | $141,865 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | Kalofonos IsabelChief Commercial Officer | Disposition To IssuerDirect | 34,000 | $85 | $2.9M | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | Kalofonos IsabelChief Commercial Officer | Disposition To IssuerDirect | 97,500 | $44 | $4.3M | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | Kalofonos IsabelChief Commercial Officer | Disposition To IssuerDirect | 55,000 | $41 | $2.3M | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 397.52% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 99.06% · OPTIONAL
Research & development changed +24.3% from the comparable as-filed period.
SBC / revenue changed -243479 basis points from the comparable as-filed period.
Revenue changed +2336.3% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
Operating income changed -2.6% from the comparable as-filed period.
Net income changed -4.5% from the comparable as-filed period.
Stock-based compensation changed -4.8% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-059885| Sep 1, 2026Filed Sep 1, 2026 |
| WIERENGA WENDELLDirector |
| Disposition To IssuerDirect |
| 116,146 |
| $85 |
| $9.9M |
| Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 5,925 | $85 | $503,625 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 12,500 | $62 | $772,000 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 12,500 | $62 | $772,125 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 17,500 | $65 | $1.1M | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 17,500 | $67 | $1.2M | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 17,500 | $65 | $1.1M | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 12,500 | $40 | $503,625 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 10,350 | $53 | $545,135 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 1, 2026 | WIERENGA WENDELLDirector | Disposition To IssuerDirect | 9,730 | $49 | $478,035 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 24, 2026 | Schilke TobinChief Financial & Infra. Ofcr. | Grant Or AwardDirect | 471 | $0 | $0 | Form 4 ↗ |
| Aug 7, 2026Filed Aug 11, 2026 | Struthers Richard ScottPresident & CEO | Option ExerciseDirect | 3,969 | $25 | $99,979 | Form 4 ↗ |
| Aug 7, 2026Filed Aug 11, 2026 | Struthers Richard ScottPresident & CEO | Option ExerciseDirect | 4,422 | $23 | $99,981 | Form 4 ↗ |
| Aug 7, 2026Filed Aug 11, 2026 | Struthers Richard ScottPresident & CEO | Option ExerciseDirect | 6,542 | $15 | $100,027 | Form 4 ↗ |
| Aug 7, 2026Filed Aug 11, 2026 | Struthers Richard ScottPresident & CEO | Option ExerciseDirect | 4,995 | $20 | $100,000 | Form 4 ↗ |
| Aug 7, 2026Filed Aug 11, 2026 | Struthers Richard ScottPresident & CEO | Option ExerciseDirect | 3,969 | $0 | $0 | Form 4 ↗ |